A manifest of our clinical trials

Primary Outcome: Day 90 mortality for pneumonia patients >>

Trial Update: The MEGA-ROX trial has now hit 25,000 enrolments worldwide with only 15,000 more to go >>

Trial Update: An adaptive platform design, running multiple domains concurrently >>

  • ASCOT

    »ASCOT: A clinical trial that will generate clinical evidence on treatment for COVID-19, which can be applied during a pandemic to reduce mortality.

  • CAPTIVATE

    »CAPTIVATE: The Global Kidney Patient Trials Network (GKPTN) registry has enrolled 4334 patients with chronic kidney disease since May 2020 across 119 sites in 8 countries.

  • REDUSE

    »REDUSE: Integrating research for human-centred treatment in septic shock.

  • ROADMAP

    »ROADMAP: A global, Bayesian adaptive platform trial assessing both surgical and antibiotic interventions to optimise treatment outcomes.

  • SNAP

    »SNAP: Aims to improve treatment outcomes for patients with Staphylococcus aureus bloodstream infections.

  • STEPCARE

    »STEPCARE: Aims to determine the optimal intensive care treatment for patients after arrival in hospital.

Enrolment: 352 patients
18+ years, all genders.

This trial aims to systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity and knee osteoarthritis based on indicators such as BMI, waist circumference, and body weight.

  • T1D PLUS

    »T1D PLUS: This trial involves 40 sites across Europe, including the UK, Austria, France, Belgium, Germany, and Italy. 

  • TTM2

    »TTM2: This trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit.

  • ENGAGE EARLY

    »CONTACT: Engage Spiral early to define resources, navigate regulation, and optimise your trial design.